An End-to-End Integrated Solutions Approach to Commercial Viral Vector Manufacturing

[Available On-Demand]
Search General Info
With several recent FDA approvals and a strong drug pipeline, gene therapy is coming of age. With this comes the requirement to ensure that there are robust manufacturing processes in place in order to scale with demand and to make these therapies readily accessible to those who need them. However, current manufacturing processes for gene therapies have often been developed with limited scalability in mind and large shifts in technology have to take place to enable industrialization. This also has to be done while keeping costs in mind. In this talk we will discuss the importance of establishing robust, scalable manufacturing operations and demonstrate its impact on future manufacturability of gene therapies.

Speaker - Jeremy Rautenbach, Global Product Manager Biotech Integrated Solutions, Pall Biotech